Compare DexCom, Inc. (DXCM) vs Sea Limited (SE) Price & Performance

DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.

The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.

Sea Limited (SE) trades at $109.29, down 1.24% on the day, with a bullish technical signal and strong support at $108. The company reported robust revenue growth, with 2025 revenue reaching $22.94B and net income of $1.58B, though recent quarterly earnings have been mixed. Positive cash flow trends and a high analyst buy rating of 70.45% reflect confidence, but insider selling and elevated valuation ratios present cautionary notes.

The outlook for SE is cautiously optimistic, driven by sustained revenue expansion and improving profitability. Key risks include recent insider share sales and high P/E ratio of 43.84, suggesting the stock may be fully valued. The consensus price target of $131.00 indicates potential upside, but investors should weigh growth prospects against valuation concerns and competitive pressures in Southeast Asian markets.